{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:57:31Z","timestamp":1773262651888,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["384\/2025"],"award-info":[{"award-number":["384\/2025"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["450\/2024"],"award-info":[{"award-number":["450\/2024"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s43440-026-00821-1","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:23:12Z","timestamp":1768285392000},"page":"582-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selected tryptophan metabolites and inflammatory molecules in hemodialyzed patients"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5251-7763","authenticated-orcid":false,"given":"Izabela","family":"Zakrocka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9079-8594","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Kozio\u0142","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-8340","authenticated-orcid":false,"given":"Rados\u0142aw","family":"Mlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Wi\u0119ckowska\u2013Dero\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3732-4336","authenticated-orcid":false,"given":"Natalia","family":"Moniczewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-6241","authenticated-orcid":false,"given":"Sylwia","family":"Boczkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Kloc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7587-2626","authenticated-orcid":false,"given":"Tomasz","family":"Kocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-8341","authenticated-orcid":false,"given":"Alina","family":"Olender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-528X","authenticated-orcid":false,"given":"Ewa M.","family":"Urba\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-3236","authenticated-orcid":false,"given":"Wojciech","family":"Za\u0142uska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-2946","authenticated-orcid":false,"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"821_CR1","doi-asserted-by":"publisher","first-page":"e1378","DOI":"10.1016\/S2214-109X(25)00198-6","volume":"13","author":"GBD 2023 Kidney Failure with Replacement Therapy Collaborators","year":"2025","unstructured":"GBD 2023 Kidney Failure with Replacement Therapy Collaborators. Global, regional, and National prevalence of kidney failure with replacement therapy and associated aetiologies, 1990\u20132023: a systematic analysis for the global burden of disease study 2023. Lancet Glob Heal. 2025;13:e1378\u20131395.","journal-title":"Lancet Glob Heal"},{"key":"821_CR2","doi-asserted-by":"crossref","unstructured":"Boenink R, Bonthuis M, Boerstra BA, Astley ME, Montez de Sousa IR, Helve J, et al. The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparisons. Clin Kidney J. 2025;18:sfae405.","DOI":"10.1093\/ckj\/sfaf107"},{"key":"821_CR3","doi-asserted-by":"crossref","unstructured":"Boerstra BA, Boenink R, Astley ME, Bonthuis M, Abd ElHafeez S, Arribas Monz\u00f3n F, et al. The ERA Registry Annual Report 2021: a summary. Clin Kidney J. 2024;17:sfad281.","DOI":"10.1093\/ckj\/sfad281"},{"key":"821_CR4","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.3390\/jcm14082614","volume":"14","author":"B Canaud","year":"2025","unstructured":"Canaud B, Strippoli G, Davenport A. High-Volume hemodiafiltration versus High-Flux hemodialysis: A narrative review for the clinician. J Clin Med. 2025;14:2614.","journal-title":"J Clin Med"},{"key":"821_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/toxins12040234","volume":"12","author":"MK van Gelder","year":"2020","unstructured":"van Gelder MK, Middel IR, Vernooij RWM, Bots ML, Verhaar MC, Masereeuw R, et al. Protein-Bound uremic toxins in Hemodialysis patients relate to residual kidney Function, are not influenced by convective Transport, and do not relate to outcome. Toxins (Basel). 2020;12:234.","journal-title":"Toxins (Basel)"},{"key":"821_CR6","doi-asserted-by":"publisher","first-page":"2498093","DOI":"10.1080\/0886022X.2025.2498093","volume":"47","author":"L Gan","year":"2025","unstructured":"Gan L, Gu L, Ge Y, Lin H, Li Y, Chen F, et al. Comparison of middle molecule removal with expanded Hemodialysis versus haemodiafiltration among Chinese Hemodialysis patients. Ren Fail. 2025;47:2498093.","journal-title":"Ren Fail"},{"key":"821_CR7","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.2741\/4363","volume":"20","author":"M-H Zou","year":"2015","unstructured":"Zou M-H. Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation. Front Biosci. 2015;20:4363.","journal-title":"Front Biosci"},{"key":"821_CR8","doi-asserted-by":"publisher","first-page":"686412","DOI":"10.3389\/fmolb.2021.686412","volume":"8","author":"B Groth","year":"2021","unstructured":"Groth B, Venkatakrishnan P, Lin S-J, NAD\u2009+\u2009Metabolism. Metabolic Stress, and infection. Front Mol Biosci. 2021;8:686412.","journal-title":"Front Mol Biosci"},{"key":"821_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s43440-021-00329-w","volume":"74","author":"I Zakrocka","year":"2022","unstructured":"Zakrocka I, Za\u0142uska W. Kynurenine pathway in kidney diseases. Pharmacol Rep. 2022;74:27\u201339.","journal-title":"Pharmacol Rep"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"117864692095488","DOI":"10.1177\/1178646920954882","volume":"13","author":"A Mor","year":"2020","unstructured":"Mor A, Kalaska B, Pawlak D. Kynurenine pathway in chronic kidney disease: what\u2019s Old, what\u2019s New, and what\u2019s next? Int J Tryptophan Res. 2020;13:117864692095488.","journal-title":"Int J Tryptophan Res"},{"key":"821_CR11","doi-asserted-by":"publisher","first-page":"101573","DOI":"10.1016\/j.arr.2022.101573","volume":"75","author":"A Salminen","year":"2022","unstructured":"Salminen A. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process. Ageing Res Rev. 2022;75:101573.","journal-title":"Ageing Res Rev"},{"key":"821_CR12","doi-asserted-by":"publisher","first-page":"e2300218","DOI":"10.1002\/mnfr.202300218","volume":"67","author":"Y Hui","year":"2023","unstructured":"Hui Y, Zhao J, Yu Z, Wang Y, Qin Y, Zhang Y, et al. The role of Tryptophan metabolism in the occurrence and progression of acute and chronic kidney diseases. Mol Nutr Food Res. 2023;67:e2300218.","journal-title":"Mol Nutr Food Res"},{"key":"821_CR13","doi-asserted-by":"publisher","first-page":"13537","DOI":"10.3390\/ijms241713537","volume":"24","author":"S Guerra-Ojeda","year":"2023","unstructured":"Guerra-Ojeda S, Suarez A, Valls A, Verd\u00fa D, Pereda J, Ortiz-Zapater E, et al. The role of Aryl hydrocarbon receptor in the endothelium: A systematic review. Int J Mol Sci. 2023;24:13537.","journal-title":"Int J Mol Sci"},{"key":"821_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1681\/ASN.2017080929","volume":"29","author":"VB Kolachalama","year":"2018","unstructured":"Kolachalama VB, Shashar M, Alousi F, Shivanna S, Rijal K, Belghasem ME, et al. Uremic Solute-Aryl hydrocarbon Receptor-Tissue factor axis associates with thrombosis after vascular injury in humans. J Am Soc Nephrol. 2018;29:1063\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"821_CR15","doi-asserted-by":"publisher","first-page":"782199","DOI":"10.3389\/fphar.2022.782199","volume":"13","author":"CS Curran","year":"2022","unstructured":"Curran CS, Kopp JB. Aryl hydrocarbon receptor mechanisms affecting chronic kidney disease. Front Pharmacol. 2022;13:782199.","journal-title":"Front Pharmacol"},{"key":"821_CR16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00109-007-0278-y","volume":"85","author":"M Nangaku","year":"2007","unstructured":"Nangaku M, Eckardt K-U. Hypoxia and the HIF system in kidney disease. J Mol Med. 2007;85:1325\u201330.","journal-title":"J Mol Med"},{"key":"821_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12882-025-04193-1","volume":"26","author":"A Gen\u00e7ler","year":"2025","unstructured":"Gen\u00e7ler A, \u00c7elik H, Padal\u0131 F, Demir A, Kafadar S. Hypoxia-inducible factor-1 alpha and nuclear factor erythroid 2-related factor 2 as biomarkers of renal scarring in children with congenital anomalies of the kidney and urinary tract: a prospective case-control study. BMC Nephrol. 2025;26:277.","journal-title":"BMC Nephrol"},{"key":"821_CR18","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.3390\/s24175481","volume":"24","author":"Z Zielinska","year":"2024","unstructured":"Zielinska Z, Oldak L, Guszcz T, Hermanowicz A, Gorodkiewicz E. SPRi biosensor for simultaneous determination of HIF-1\u03b1, Angiopoietin-2, and Interleukin-1\u03b2 in blood plasma. Sensors. 2024;24:5481.","journal-title":"Sensors"},{"key":"821_CR19","doi-asserted-by":"publisher","first-page":"300060523120213","DOI":"10.1177\/03000605231202139","volume":"51","author":"Z Tong","year":"2023","unstructured":"Tong Z, Wang G, Huang W, Zhang H, Xie F, Wang X. Hypoxia-inducible factor-1\u03b1 is a biomarker for predicting patients with sepsis. J Int Med Res. 2023;51:3000605231202139.","journal-title":"J Int Med Res"},{"key":"821_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.thromres.2007.01.011","volume":"120","author":"K Pawlak","year":"2007","unstructured":"Pawlak K, Pawlak D, Mysliwiec M. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in Hemodialysis patients. Thromb Res. 2007;120:871\u20136.","journal-title":"Thromb Res"},{"key":"821_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000524965","volume":"8","author":"YR Sudhini","year":"2022","unstructured":"Sudhini YR, Wei C, Reiser J. SuPAR: an inflammatory mediator for kidneys. Kidney Dis. 2022;8:265\u201374.","journal-title":"Kidney Dis"},{"key":"821_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","volume":"17","author":"C Wei","year":"2011","unstructured":"Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17:952\u201360.","journal-title":"Nat Med"},{"key":"821_CR23","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","volume":"373","author":"SS Hayek","year":"2015","unstructured":"Hayek SS, Sever S, Ko Y-A, Trachtman H, Awad M, Wadhwani S, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373:1916\u201325.","journal-title":"N Engl J Med"},{"key":"821_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ekir.2018.05.004","volume":"3","author":"C Torino","year":"2018","unstructured":"Torino C, Pizzini P, Cutrupi S, Postorino M, Tripepi G, Mallamaci F, et al. Soluble urokinase plasminogen activator receptor (suPAR) and All-Cause and cardiovascular mortality in diverse Hemodialysis patients. Kidney Int Rep. 2018;3:1100\u20139.","journal-title":"Kidney Int Rep"},{"key":"821_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/MAJ.0b013e3181b922a4","volume":"339","author":"K Pawlak","year":"2010","unstructured":"Pawlak K, Buraczewska-Buczko A, Pawlak D, Mysliwiec M, Hyperfibrinolysis. uPA\/suPAR System, Kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on Conservative treatment. Am J Med Sci. 2010;339:5\u20139.","journal-title":"Am J Med Sci"},{"key":"821_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.5301\/ijao.5000456","volume":"38","author":"J Sternby","year":"2015","unstructured":"Sternby J, Daugirdas JT. Theoretical basis for and improvement of daugirdas\u2019 second generation formula for single-pool Kt\/V. Int J Artif Organs. 2015;38:632\u20137.","journal-title":"Int J Artif Organs"},{"key":"821_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jchromb.2010.01.006","volume":"878","author":"J Zhao","year":"2010","unstructured":"Zhao J, Gao P, Zhu D. Optimization of Zn2+-containing mobile phase for simultaneous determination of kynurenine, kynurenic acid and Tryptophan in human plasma by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:603\u20138.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"821_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0378-4347(00)83925-0","volume":"428","author":"MP Heyes","year":"1988","unstructured":"Heyes MP, Quearry BJ. Quantification of 3-hydroxykynurenine in brain by high-performance liquid chromatography and electrochemical detection. J Chromatogr. 1988;428:340\u20134.","journal-title":"J Chromatogr"},{"key":"821_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0140-6736(87)90266-2","volume":"1","author":"J Bergstr\u00f6m","year":"1987","unstructured":"Bergstr\u00f6m J, Wehle B. No change in corrected beta 2-microglobulin concentration after Cuprophane haemodialysis. Lancet (London England). 1987;1:628\u20139.","journal-title":"Lancet (London England)"},{"key":"821_CR30","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/j.ekir.2024.06.039","volume":"9","author":"S Al Awadhi","year":"2024","unstructured":"Al Awadhi S, Myint L, Guallar E, Clish CB, Wulczyn KE, Kalim S, et al. A metabolomics approach to identify metabolites associated with mortality in patients receiving maintenance Hemodialysis. Kidney Int Rep. 2024;9:2718\u201326.","journal-title":"Kidney Int Rep"},{"key":"821_CR31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/toxins16110463","volume":"16","author":"R Vanholder","year":"2024","unstructured":"Vanholder R, Snauwaert E, Verbeke F, Glorieux G. Future of uremic toxin management. Toxins (Basel). 2024;16:463.","journal-title":"Toxins (Basel)"},{"key":"821_CR32","doi-asserted-by":"publisher","first-page":"sfad248","DOI":"10.1093\/ckj\/sfad248","volume":"17","author":"C El Chamieh","year":"2024","unstructured":"El Chamieh C, Larabi IA, Alencar De Pinho N, Lambert O, Combe C, Fouque D, et al. Study of the association between serum levels of kynurenine and cardiovascular outcomes and overall mortality in chronic kidney disease. Clin Kidney J. 2024;17:sfad248.","journal-title":"Clin Kidney J"},{"key":"821_CR33","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/ndt\/gfn739","volume":"24","author":"JC Schefold","year":"2009","unstructured":"Schefold JC, Zeden JP, Fotopoulou C, Von Haehling S, Pschowski R, Hasper D, et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of Tryptophan catabolites in patients with chronic kidney disease: A possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transpl. 2009;24:1901\u20138.","journal-title":"Nephrol Dial Transpl"},{"key":"821_CR34","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1023\/A:1015238418500","volume":"33","author":"D Pawlak","year":"2001","unstructured":"Pawlak D, Pawlak K, Malyszko J, Mysliwiec M, Buczko W. Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol. 2001;33:399\u2013404.","journal-title":"Int Urol Nephrol"},{"key":"821_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3349\/ymj.2020.61.1.56","volume":"61","author":"JT Kim","year":"2020","unstructured":"Kim JT, Kim SH, Min HK, Jeon SJ, Sung SA, Park WH, et al. Effect of Dialysis on Aryl hydrocarbon receptor transactivating activity in patients with chronic kidney disease. Yonsei Med J. 2020;61:56\u201363.","journal-title":"Yonsei Med J"},{"key":"821_CR36","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2017.11.010","volume":"93","author":"L Dou","year":"2018","unstructured":"Dou L, Poitevin S, Sall\u00e9e M, Addi T, Gondouin B, McKay N, et al. Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. Kidney Int. 2018;93:986\u201399.","journal-title":"Kidney Int"},{"key":"821_CR37","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.3390\/ijms26115384","volume":"26","author":"Y-C Cheng","year":"2025","unstructured":"Cheng Y-C, Huang W-C, Li Y-H, Liu S-S, Sheu M-L, Lee I-T. Circulating Aryl hydrocarbon receptor is associated with latent tuberculosis infection in patients with type 2 diabetes. Int J Mol Sci. 2025;26:5384.","journal-title":"Int J Mol Sci"},{"key":"821_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.14712\/fb2018064030097","volume":"64","author":"M Ber\u00e1nek","year":"2018","unstructured":"Ber\u00e1nek M, Fiala Z, Kreml\u00e1\u010dek J, Andr\u00fds C, Krejsek J, Ham\u00e1kov\u00e1 K, et al. Serum levels of Aryl hydrocarbon Receptor, cytochromes P450 1A1 and 1B1 in patients with exacerbated psoriasis vulgaris. Folia Biol (Praha). 2018;64:97\u2013102.","journal-title":"Folia Biol (Praha)"},{"key":"821_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11255-017-1778-5","volume":"50","author":"RN Wlaze\u0142","year":"2018","unstructured":"Wlaze\u0142 RN, Szadkowska I, Bartnicki P, Ro\u015bniak-B\u0105k K, Rysz J. Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in Hemodialysis patients. Int Urol Nephrol. 2018;50:339\u201345.","journal-title":"Int Urol Nephrol"},{"key":"821_CR40","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.3390\/ijms26125747","volume":"26","author":"A Bratsiakou","year":"2025","unstructured":"Bratsiakou A, Papasotiriou M, Davoulou P, Georgopoulou GA, Papachristou E, Goumenos DS. Efficacy of expanded Hemodialysis and comparison with standard Hemodialysis and online hemodiafiltration. Int J Mol Sci. 2025;26:5747.","journal-title":"Int J Mol Sci"},{"key":"821_CR41","doi-asserted-by":"publisher","first-page":"5309328","DOI":"10.1155\/2016\/5309328","volume":"2016","author":"CL Lamb","year":"2016","unstructured":"Lamb CL, Cholico GN, Perkins DE, Fewkes MT, Oxford JT, Lujan TJ, et al. Aryl hydrocarbon receptor activation by TCDD modulates expression of extracellular matrix remodeling genes during experimental liver fibrosis. Biomed Res Int. 2016;2016:5309328.","journal-title":"Biomed Res Int"},{"key":"821_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1006\/taap.1995.1124","volume":"133","author":"KW Gaido","year":"1995","unstructured":"Gaido KW, Maness SC. Post-transcriptional stabilization of urokinase plasminogen activator mRNA by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a human keratinocyte cell line. Toxicol Appl Pharmacol. 1995;133:34\u201342.","journal-title":"Toxicol Appl Pharmacol"},{"key":"821_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.thromres.2006.03.011","volume":"119","author":"K Pawlak","year":"2007","unstructured":"Pawlak K, Pawlak D, Mysliwiec M. Excess soluble urokinase-type plasminogen activator receptor in the plasma of Dialysis patients correlates with increased fibrinolytic activity. Thromb Res. 2007;119:475\u201380.","journal-title":"Thromb Res"},{"key":"821_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.thromres.2007.10.017","volume":"122","author":"K Pawlak","year":"2008","unstructured":"Pawlak K, Mysliwiec M, Pawlak D. The urokinase-type plasminogen activator\/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb Res. 2008;122:328\u201335.","journal-title":"Thromb Res"},{"key":"821_CR45","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3892\/or.2015.4449","volume":"35","author":"H Nishi","year":"2016","unstructured":"Nishi H, Sasaki T, Nagamitsu Y, Terauchi F, Nagai T, Nagao T, et al. Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasminogen activator receptor gene transcription during hypoxia in cervical cancer cells. Oncol Rep. 2016;35:992\u20138.","journal-title":"Oncol Rep"},{"key":"821_CR46","first-page":"460","volume":"12","author":"K Kozie\u0142","year":"2023","unstructured":"Kozie\u0142 K, Urbanska EM. Kynurenine pathway in diabetes Mellitus\u2014Novel. Pharmacol Target? Cells. 2023;12:460.","journal-title":"Pharmacol Target? Cells"},{"key":"821_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s11658-022-00397-7","volume":"27","author":"TS Sayed","year":"2022","unstructured":"Sayed TS, Maayah ZH, Zeidan HA, Agouni A, Korashy HM. Insight into the physiological and pathological roles of the Aryl hydrocarbon receptor pathway in glucose homeostasis, insulin resistance, and diabetes development. Cell Mol Biol Lett. 2022;27:103.","journal-title":"Cell Mol Biol Lett"},{"key":"821_CR48","doi-asserted-by":"publisher","first-page":"27447","DOI":"10.1038\/s41598-024-65643-8","volume":"14","author":"M Ingwiller","year":"2024","unstructured":"Ingwiller M, Bozman D-F, Florens N, Cerasuolo D, Vigneau C, Couchoud C, et al. Diuretics and mortality reduction in incident Dialysis patients: a two-year observational study. Sci Rep. 2024;14:27447.","journal-title":"Sci Rep"},{"key":"821_CR49","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/1744-9987.12576","volume":"21","author":"P de Sequera","year":"2017","unstructured":"de Sequera P, Corchete E, Bohorquez L, Albalate M, Perez-Garcia R, Alique M, et al. Residual renal function in Hemodialysis and inflammation. Ther Apher Dial. 2017;21:592\u20138.","journal-title":"Ther Apher Dial"},{"key":"821_CR50","doi-asserted-by":"publisher","first-page":"20421","DOI":"10.1038\/s41598-025-07497-2","volume":"15","author":"B Canaud","year":"2025","unstructured":"Canaud B, Davenport A, Morena-Carrere M, Amico M, Molinari N, Cristol J-P. Continuous beta-2 microglobulin-based clearance highlights superiority of high-Dose HDF over high-flux HD in predicting outcomes. Sci Rep. 2025;15:20421.","journal-title":"Sci Rep"},{"key":"821_CR51","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1093\/ndt\/gfaf024","volume":"40","author":"Y Battaglia","year":"2025","unstructured":"Battaglia Y, Shroff R, Meijers B, Nistor I, Alfano G, Franssen C, et al. Haemodiafiltration versus high-flux haemodialysis - a consensus statement from the EuDial working group of the ERA. Nephrol Dial Transpl. 2025;40:1590\u2013614.","journal-title":"Nephrol Dial Transpl"},{"key":"821_CR52","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1038\/s41598-025-89197-5","volume":"15","author":"E Lukkanalikitkul","year":"2025","unstructured":"Lukkanalikitkul E, Kidkaem H, Phonrat M, Prathompong P, Anutrakulchai S. A randomized trial comparing medium cut-off membrane dialyzers with online hemodiafiltration for uremic toxins clearance in Hemodialysis patients. Sci Rep. 2025;15:5467.","journal-title":"Sci Rep"},{"key":"821_CR53","doi-asserted-by":"publisher","first-page":"104869","DOI":"10.1016\/j.phrs.2020.104869","volume":"159","author":"NR Coelho","year":"2020","unstructured":"Coelho NR, Tomkiewicz C, Correia MJ, Gon\u00e7alves-Dias C, Barouki R, Pereira SA, et al. First evidence of Aryl hydrocarbon receptor as a druggable target in hypertension induced by chronic intermittent hypoxia. Pharmacol Res. 2020;159:104869.","journal-title":"Pharmacol Res"},{"key":"821_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1474-8673.2008.00418.x","volume":"28","author":"R Villalobos-Molina","year":"2008","unstructured":"Villalobos-Molina R, V\u00e1zquez-Cuevas FG, L\u00f3pez-Guerrero JJ, Figueroa-Garc\u00eda MC, Gallardo-Ortiz IA, Ibarra M, et al. Vascular alpha-1D-adrenoceptors are overexpressed in aorta of the Aryl hydrocarbon receptor null mouse: role of increased angiotensin II. Auton Autacoid Pharmacol. 2008;28:61\u20137.","journal-title":"Auton Autacoid Pharmacol"},{"key":"821_CR55","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/jbmr.5650061009","volume":"6","author":"G Leloup","year":"1991","unstructured":"Leloup G, Peeters-Joris C, Delaisse JM, Opdenakker G, Vaes G. Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone. J Bone Min Res. 1991;6:1081\u201390.","journal-title":"J Bone Min Res"},{"key":"821_CR56","doi-asserted-by":"crossref","unstructured":"Ketteler M, Evenepoel P, Holden RM, Isakova T, J\u00f8rgensen HS, Komaba H, et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;107:405\u2013423.","DOI":"10.1016\/j.kint.2024.11.013"},{"key":"821_CR57","doi-asserted-by":"publisher","first-page":"iii624","DOI":"10.1093\/ndt\/gfv200.66","volume":"30","author":"I Griveas","year":"2015","unstructured":"Griveas I, Andriopoulos C, Sitaras P, Aktsiali M. Soluble urokinase plasminogen receptor (supar): a future risk marker for Hemodialysis patients? Nephrol Dial Transpl. 2015;30:iii624\u2013624.","journal-title":"Nephrol Dial Transpl"},{"key":"821_CR58","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.ekir.2023.08.038","volume":"8","author":"C Sommerer","year":"2023","unstructured":"Sommerer C, M\u00fcller-Krebs S, Nadal J, Schultheiss UT, Friedrich N, Nauck M, et al. Prospective cohort study of soluble urokinase plasminogen activation receptor and cardiovascular events in patients with CKD. Kidney Int Rep. 2023;8:2265\u201375.","journal-title":"Kidney Int Rep"},{"key":"821_CR59","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.thromres.2007.07.017","volume":"121","author":"K Pawlak","year":"2008","unstructured":"Pawlak K, Pawlak D, Mysliwiec M. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients. Thromb Res. 2008;121:787\u201391.","journal-title":"Thromb Res"},{"key":"821_CR60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/FJC.0000000000000565","volume":"71","author":"M Ekholm","year":"2018","unstructured":"Ekholm M, Jekell A, Wall\u00e9n NH, Gigante B, Kahan T. Effects of Angiotensin-Converting enzyme Inhibition and alpha 1-Adrenergic receptor Blockade on inflammation and hemostasis in human hypertension. J Cardiovasc Pharmacol. 2018;71:240\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"821_CR61","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1053\/j.ajkd.2020.07.018","volume":"77","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Knoll GA, Petrcich W, Hiremath S, Ruzicka M, Burns KD, et al. Kidney, Cardiac, and safety outcomes associated with \u03b1-Blockers in patients with CKD: A Population-Based cohort study. Am J Kidney Dis. 2021;77:178\u2013e1891.","journal-title":"Am J Kidney Dis"},{"key":"821_CR62","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/ki.2014.197","volume":"87","author":"B Meijers","year":"2015","unstructured":"Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int. 2015;87:210\u20136.","journal-title":"Kidney Int"},{"key":"821_CR63","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1158\/0008-5472.CAN-05-2351","volume":"66","author":"HJ Knowles","year":"2006","unstructured":"Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL. Normoxic stabilization of Hypoxia-Inducible Factor-1\u03b1 by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural Resistance\u2013Associated macrophage protein 1. Cancer Res. 2006;66:2600\u20137.","journal-title":"Cancer Res"},{"key":"821_CR64","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2215\/CJN.10881016","volume":"12","author":"C Drechsler","year":"2017","unstructured":"Drechsler C, Hayek SS, Wei C, Sever S, Genser B, Krane V, et al. Soluble urokinase plasminogen activator receptor and outcomes in patients with diabetes on Hemodialysis. Clin J Am Soc Nephrol. 2017;12:1265\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"key":"821_CR65","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1515\/revneuro-2024-0065","volume":"36","author":"AG Bertollo","year":"2025","unstructured":"Bertollo AG, Mingoti MED, Ign\u00e1cio ZM. Neurobiological mechanisms in the kynurenine pathway and major depressive disorder. Rev Neurosci. 2025;36:169\u201387.","journal-title":"Rev Neurosci"},{"key":"821_CR66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bbi.2020.01.011","volume":"87","author":"Y Sun","year":"2020","unstructured":"Sun Y, Drevets W, Turecki G, Li QS. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to Escitalopram and desvenlafaxine. Brain Behav Immun. 2020;87:404\u201312.","journal-title":"Brain Behav Immun"},{"key":"821_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2015.02.029","volume":"48","author":"S Guloksuz","year":"2015","unstructured":"Guloksuz S, Arts B, Walter S, Drukker M, Rodriguez L, Myint A-M, et al. The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway. Brain Behav Immun. 2015;48:48\u201352.","journal-title":"Brain Behav Immun"},{"key":"821_CR68","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1471-4159.1998.70010299.x","volume":"70","author":"S Okuda","year":"1998","unstructured":"Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998;70:299\u2013307.","journal-title":"J Neurochem"},{"key":"821_CR69","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0361-9230(02)00813-4","volume":"58","author":"J Topczewska-Bruns","year":"2002","unstructured":"Topczewska-Bruns J, Pawlak D, Chabielska E, Tankiewicz A, Buczko W. Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency. Brain Res Bull. 2002;58:423\u201338.","journal-title":"Brain Res Bull"},{"key":"821_CR70","unstructured":"Mafrici B, Viramontes-H\u00f6rner D, Gardner DS, Smith K, Taal MW, Selby NM, et al. Amino acid and protein losses in adult patients receiving maintenance dialysis: A literature review. J Ren Nutr. 2025;S1051-2276(25)00156-6."},{"key":"821_CR71","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.jrn.2019.12.003","volume":"30","author":"S Murtas","year":"2020","unstructured":"Murtas S, Aquilani R, Iadarola P, Deiana ML, Secci R, Cadeddu M, et al. Differences and effects of metabolic fate of individual amino acid loss in High-Efficiency Hemodialysis and hemodiafiltration. J Ren Nutr. 2020;30:440\u201351.","journal-title":"J Ren Nutr"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00821-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00821-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00821-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:42:43Z","timestamp":1773204163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00821-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00821-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Bioethical Committee at the Medical University, Lublin, Poland (number KE-0024\/6\/01\/2025), and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}